Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
-
Patent number: 8003763Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.Type: GrantFiled: December 22, 2008Date of Patent: August 23, 2011Assignee: Biogen IDEC MA Inc.Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
-
Patent number: 8003098Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.Type: GrantFiled: February 22, 2007Date of Patent: August 23, 2011Assignee: Oncotherapy Science, Inc.Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima, Yoshiro Kishi, Motoki Kuhara, Shiyo Nishida, Midori Shinohara
-
Patent number: 8003761Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: January 22, 2008Date of Patent: August 23, 2011Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Publication number: 20110200606Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.Type: ApplicationFiled: February 4, 2011Publication date: August 18, 2011Inventors: Scott Alan McCauley, Hector Rodriguez, Carlos A. Garcia, Victoria Smith
-
Publication number: 20110200623Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: ApplicationFiled: July 23, 2009Publication date: August 18, 2011Applicant: HANMI HOLDINGS CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20110200536Abstract: The present invention relates to chelators, in particular to chelators which are capable of forming complexes, i.e. paramagnetic chelates, with paramagnetic metal ions. The invention also relates to said paramagnetic chelates, said paramagnetic chelates linked to other molecules and their use as contrast agents in magnetic resonance imaging (MRI).Type: ApplicationFiled: August 12, 2008Publication date: August 18, 2011Inventors: Harry John Wadsworth, Ian Martin Newington, Dennis O'shea
-
Publication number: 20110201547Abstract: The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.Type: ApplicationFiled: January 27, 2011Publication date: August 18, 2011Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Ram Sasisekharan, Karthik Viswanathan, Venkataramanan Soundararajan, Sasi Raguram, Viswanathan Sasisekharan
-
Publication number: 20110195074Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, for monitoring the effectiveness of treatment of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, and for drug development.Type: ApplicationFiled: June 9, 2009Publication date: August 11, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Patent number: 7994135Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: GrantFiled: August 3, 2007Date of Patent: August 9, 2011Assignee: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
-
Publication number: 20110189704Abstract: Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method.Type: ApplicationFiled: August 22, 2008Publication date: August 4, 2011Applicant: Mitsubishi Chemical Medience CorporationInventors: Yoshikazu Takagi, Yuichi Shintani
-
Publication number: 20110189183Abstract: Provided herein are antibodies that immunospecifically bind to species of the genus Candida. Also provided are methods for of prevention, treatment and diagnosis of Candida infection and/or the treatment of one more symptoms of Candida infection. Methods of generating antibodies that immunospecifically bind Candida also are provided.Type: ApplicationFiled: September 17, 2010Publication date: August 4, 2011Inventors: Robert Anthony Williamson, Jehangir Wadia, Michelle Wagner
-
Patent number: 7989595Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: June 14, 2006Date of Patent: August 2, 2011Assignee: Genentech, Inc.Inventors: Mark S. Dennis, William Mallet, Paul Polakis
-
Patent number: 7989171Abstract: An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A(1-4)-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional analogues capable of binding to an antigenic epitope within the A(1-4)-D region of human tenascin.Type: GrantFiled: February 16, 2005Date of Patent: August 2, 2011Assignee: Tecnogen S.C.P.A.Inventors: Rita De Santis, Angela Pelliccia, Giovanna Palombo, Paolo Carminati
-
Patent number: 7989594Abstract: The present invention provides antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1. Also provided are antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1 to which one or more effector molecules are attached.Type: GrantFiled: July 1, 2004Date of Patent: August 2, 2011Assignee: Celltech R & D LimitedInventors: David Paul Humphreys, Sam Philip Heywood
-
Publication number: 20110182878Abstract: The subject of the present invention is an anti-ricin antibody and the use thereof for the treatment of an individual suffering from ricin poisoning.Type: ApplicationFiled: October 10, 2008Publication date: July 28, 2011Applicant: ETAT FRANCAIS represente par le Delegue General pour I'ArmementInventors: Philippe Thullier, Michael Hust, Stefan Dubel
-
Publication number: 20110182904Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to BMP2, BMP4, BMPR1A, BMPR1B, ACTR1, and/or BMPR2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Also provided are immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention and, optionally, one or more additional therapeutic. The invention also provides methods for treating diseases associated with abnormal bone formation and ossification mediated by BMP2, BMP4, BMPR1A, BMPR1B, ACTR15 and/or BMPR2.Type: ApplicationFiled: September 5, 2007Publication date: July 28, 2011Inventors: Deborah Zimmerman, Mark Selby, Mohan Srinivasan, Alasdair Bell, Sujata Singh, Richard Theolis, Heidi N. Leblanc, Kyra D. Zens, Timothy William Sproul
-
Publication number: 20110184147Abstract: The present invention provides a substrate of TGase represented by (fluorescent group)-(linker)-(a portion containing a Gln residue capable of recognition by transglutaminase (TGase))-R, wherein the fluorescent group is fluorescein isothiocyanate (FITC), Texas Red (TE) or dansyl (Dns) or a group derived therefrom; the linker is a group represented by —NH—(CH2)n—CO— (n is an integer of 1 to 6); the portion containing a Gln residue capable of recognition by TGase is a group derived from a peptide selected from among QG and the like; and R is a hydroxyl group, or biotin, nucleic acid, azide, alkyne, maleimide or cyclopentadiene, or a group derived therefrom.Type: ApplicationFiled: July 3, 2009Publication date: July 28, 2011Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Noriho Kamiya, Masahiro Goto, Hiroki Abe
-
Publication number: 20110182855Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via a nucleophilic moiety; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two nucleophilic moieties; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via nucType: ApplicationFiled: March 31, 2011Publication date: July 28, 2011Applicant: POLYTHERICS LIMITEDInventors: Stephen James BROCCHINI, Antony Robert Godwin, Elisa Pedone, Ji-Won Choi, Sunil Shaunak
-
Patent number: 7985843Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.Type: GrantFiled: October 30, 2007Date of Patent: July 26, 2011Assignee: Corixa CorporationInventors: Gary R. Fanger, Steven P. Fling
-
Publication number: 20110177002Abstract: The invention pertains to a compound for detecting cell death. According to the invention, the compound comprises a cyclic polyamine unit for the complexation of a bi- or trivalent metal ion. The compound of the invention may contain a reporting tag like fluorescein or a radioisotope including substituent.Type: ApplicationFiled: July 14, 2009Publication date: July 21, 2011Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Sabine Zitzmann-Kolbe, Ulrike Bauder-Wuest, Michael Eisenhut, Doerte Oltmanns
-
Publication number: 20110177977Abstract: The present invention is directed to antibodies having specificity for a heavy chain class at the same time as having specificity for a first light chain. Such antibodies can be used in a method of detecting or monitoring a malignant plasma cell disease comprising determining in a sample the ratio between the relative amounts of immunoglobulins having: (i) a heavy chain class bound to ? light chains; and (ii) immunoglobulins having the same heavy chain class but bound to ? light chains.Type: ApplicationFiled: January 21, 2011Publication date: July 21, 2011Applicant: THE BINDING SITE GROUP LIMITEDInventor: Arthur R. BRADWELL
-
Publication number: 20110177022Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: January 4, 2011Publication date: July 21, 2011Applicant: Schering CorporationInventors: Birgit Oppmann, Rene de Waal Malefyt, Donna M. Rennick, Robert A. Kastelein, Maria T. Wiekowski, Sergio A. Lira, Satwant K. Narula
-
Patent number: 7981398Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.Type: GrantFiled: December 22, 2009Date of Patent: July 19, 2011Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 7982012Abstract: The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.Type: GrantFiled: March 10, 2009Date of Patent: July 19, 2011Assignee: Theraclone Sciences, Inc.Inventor: Ole Olsen
-
Patent number: 7982011Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.Type: GrantFiled: November 24, 2004Date of Patent: July 19, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Ira H. Pastan, Mitchell Ho, Sookhee Bang
-
Publication number: 20110171634Abstract: Provided are methods and devices for single-molecule genomic analysis. In one embodiment, the methods entail processing a double-stranded nucleic acid and characterizing said nucleic acid. These methods are useful in, e.g., determining structural variations and copy number variations between individuals.Type: ApplicationFiled: June 30, 2009Publication date: July 14, 2011Applicant: Bionanomatrix, Inc.Inventors: Ming Xiao, Parikshit A. Deshpande, Han Cao, Michael Austin, Kandaswamy Vijayan, Alexey Y. Sharonov, Michael Boyce-Jacino
-
Publication number: 20110171720Abstract: A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). From the enriched library, two sdAbs were selected, sequenced, subcloned, and expressed as fusion proteins with c-myc-His5 tags. Similarly as phage-displayed sdAbs, these soluble tagged sdAbs were shown to selectively bind to HCEC and to transmigrate across in vitro human blood-brain barrier (BBB) model. In contrast to an unrelated llama sdAb, these sdAbs were also detected in the brain after i.v. injection into mice. These small (˜13 kDa) antibody fragments have essential characteristics of brain-specific delivery vectors and can be used to facilitate drug transport across the BBB.Type: ApplicationFiled: March 21, 2011Publication date: July 14, 2011Applicant: National Research Council of Canada NRC Communications & Corporate RelationsInventors: Arumugam Muruganandam, Jasmid Tanha, Saran Narang, Danica Stanimirovic
-
Publication number: 20110171640Abstract: The present invention provides methods for isolating cell free nucleic acid, e.g., apoptotic or fetal nucleic acids and methods of detecting neoplastic cells or identifying the genetic composition of a fetus. The invention also provides magnetic particles comprising an anti-DNA antibody, and kits comprising the magnetic particles.Type: ApplicationFiled: February 6, 2009Publication date: July 14, 2011Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Ram Bhatt, Wen-Hua Fan
-
Patent number: 7977457Abstract: This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human ?-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain of a human MHC class I molecule, (vi) a third peptide linker, (vii) a variable region from a heavy chain of a scFv fragment of an antibody, and (viii) a variable region from a light chain of such scFv fragment, wherein the consecutive amino acids which correspond to (vii) and (viii) are bound together directly by a peptide bond or by consecutive amino acids which correspond to a fourth peptide linker, wherein the antibody from which the scFv fragment is derived specifically binds to mesothelin. This invention provides nucleic acid constructs encoding same, processes for producing same, compositions, and uses thereof.Type: GrantFiled: May 17, 2007Date of Patent: July 12, 2011Assignees: Teva Pharmaceutical Industries Ltd., Technion Research & Development Foundation Ltd.Inventors: Yoram Reiter, Roy Noy, Kfir Oved
-
Publication number: 20110165674Abstract: Provided herein are conjugates including a targeting vehicle coupled to an agent. The targeting vehicle includes a tachykinin receptor ligand and a reactive moiety. Conjugates including a tachykinin receptor ligand attached to an antibody or fragment thereof that is specific for an intracellular target are also provided. Also provided are methods of delivering agents to cells expressing tachykinin receptors, methods of delivering antibodies or fragments thereof to an intracellular extra-endosomal target, and methods of arresting cell growth or introducing cell death of a cancer cell.Type: ApplicationFiled: June 9, 2010Publication date: July 7, 2011Applicant: THE UNIVERSITY OF CHICAGOInventors: Anthony Kossiakoff, Shahir Rizk
-
Publication number: 20110165647Abstract: A nanoparticle conjugate comprising a nanoparticle having one or more peptide-ol compounds and one or more polyethylene glycol (PEG) compounds attached thereto. A method of producing the nanoparticle conjugate is also described.Type: ApplicationFiled: February 4, 2009Publication date: July 7, 2011Inventors: David G. Fernig, Laurence Duchesne
-
Publication number: 20110165080Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human ductal cells. Humanized forms of these antibodies, and functional fragments of these antibodies, are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. These antibodies are of use to detect and isolate pancreatic cells or a subset thereof. The antibodies can be used for in vitro or in vivo detection and/or isolation of pancreatic endocrine cells. Methods of treating a pancreatic tumor are also disclosed. In several examples, the isolated monoclonal antibodies bind pancreatic endocrine cells and can be used to detect diabetes or a pancreatic endocrine cell tumor.Type: ApplicationFiled: January 20, 2011Publication date: July 7, 2011Inventors: Markus Grompe, Philip R. Streeter, Craig Dorrell, Stephanie L. Abraham, Kelsea M. Shoop
-
Patent number: 7973138Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.Type: GrantFiled: September 25, 2008Date of Patent: July 5, 2011Assignee: Genentech, Inc.Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
-
Publication number: 20110160440Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in diagnosis and therapy.Type: ApplicationFiled: December 10, 2004Publication date: June 30, 2011Applicant: GENENCOR INTERNATIONAL, INC.Inventors: Judith A. Fox, Fiona A. Harding, Volker Schellenberger
-
Publication number: 20110158981Abstract: The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.Type: ApplicationFiled: March 7, 2011Publication date: June 30, 2011Inventors: Eugene Regis Krah, III, Robert Lawton
-
Publication number: 20110158906Abstract: The present invention provides a micelle comprising an amphiphilic block copolymer, said amphiphilic block copolymer consisting of (a) a hydrophobic polymer attached to the 5? end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 5? end of said second nucleic acid molecule; and/or (b) a hydrophobic polymer attached to the 3? end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 3? end of said second nucleic acid molecule.Type: ApplicationFiled: August 13, 2008Publication date: June 30, 2011Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Klaus Müllen, Fikri E. Alemdaroglu, Andreas Herrmann, N. Ceren Alemdaroglu, Peter Langguth
-
Patent number: 7968687Abstract: This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.Type: GrantFiled: October 17, 2008Date of Patent: June 28, 2011Assignee: Seattle Genetics, Inc.Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
-
Publication number: 20110150760Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: ApplicationFiled: November 22, 2010Publication date: June 23, 2011Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.Inventors: JASON DAMIANO, MOHAMMAD LUQMAN, DANIEL BEDINGER, LINDA MASAT, AMER MIRZA, GENEVIEVE NONET
-
Publication number: 20110151436Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: ApplicationFiled: December 23, 2010Publication date: June 23, 2011Applicant: The Government of the United States of America as represented by the Secretary, Dept. of HealthInventors: Hana Golding, Surender Khurana
-
Publication number: 20110150960Abstract: It is an object of the present invention to provide a hazardous substance removing material, which efficiently captures hazardous substances derived from microorganisms such as bacteria or viruses and rapidly inactivates them, so as to minimize the their influences on human bodies, and which is able to allow an antibody to be supported on a carrier by a simple method, and which has an improved antibody use efficiency. The present invention provides a hazardous substance removing material consisting of a carrier on which an antibody and a sugar chain affinity substance having an affinity for a sugar chain in the Fc region of the antibody are supported.Type: ApplicationFiled: July 29, 2009Publication date: June 23, 2011Inventor: Hiroshi Iwanaga
-
Publication number: 20110151538Abstract: The present invention is directed to truncated dockerin polypeptides, recombinant polypeptides and affinity systems comprising the truncated dockerin polypeptide, methods of generating same, and methods of use thereof to purify, isolate, and detect molecules of interest.Type: ApplicationFiled: August 9, 2009Publication date: June 23, 2011Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCEInventors: Edward A. Bayer, Alon Karpol, Raphael Lamed
-
Patent number: 7964195Abstract: The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: GrantFiled: January 9, 2006Date of Patent: June 21, 2011Assignee: Diadexus, Inc.Inventors: Jackie Papkoff, Kenneth R. Shroyer
-
Patent number: 7964566Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: GrantFiled: August 3, 2007Date of Patent: June 21, 2011Assignee: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
-
Patent number: 7964567Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: GrantFiled: August 3, 2007Date of Patent: June 21, 2011Assignee: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
-
Publication number: 20110144281Abstract: The present invention relates to a polymer comprising a cholane core having at least one derivatizable group covalently bonded thereto and a hydrophilic polymer chain covalently bonded to derivatizable group(s) and a process for producing it The present invention also relates to micellar aggregate formed from the polymer of the present.Type: ApplicationFiled: December 5, 2008Publication date: June 16, 2011Applicant: VALORISATION-RECHERCHE, SOCIETE EN COMMANDITEInventors: Xiao-Xia Zhu, Juntao Luo, Guillaume Giguere
-
Publication number: 20110144302Abstract: The invention provides an immunoglobulin G Fc region binding polypeptide, which polypeptide comprises an immunoglobulin G Fc region binding motif, BM, consisting of an amino acid sequence selected from: i) EQQX4AFYEIL HLPNL-TEX18QX20X21AFIX25X26LRX29, and ii) an amino acid sequence which has at least 85% identity to the sequence defined in i). Also provided are methods of isolation or production of IgG Fc-containing molecules.Type: ApplicationFiled: September 24, 2008Publication date: June 16, 2011Inventors: Anders Jarstad, Thomas Bergman, Lars Abrahmsen, Christofer Lendel, Karin Nord
-
Publication number: 20110142756Abstract: The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.Type: ApplicationFiled: October 4, 2010Publication date: June 16, 2011Inventors: George L. Mayers, Samuel Rose, David S. Rose
-
Publication number: 20110142761Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.Type: ApplicationFiled: October 15, 2010Publication date: June 16, 2011Applicant: ABBOTT LABORATORIESInventors: Chengbin Wu, Chung-ming Hsieh, Renee Miller, Dominic J. Ambrosi
-
Publication number: 20110142763Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.Type: ApplicationFiled: November 8, 2010Publication date: June 16, 2011Applicant: Raptor Pharmaceuticals Inc.Inventors: TODD ZANKEL, CHRISTOPHER M. STARR
-
Publication number: 20110142822Abstract: The present invention relates to co-crystals of cetuximab Fab in a complex with extracellular domain of EGFR, and structure coordinates obtained from such crystal. Such coordinates are useful for identifying mimetics that bind to the extracellular domain of EGFR. Such mimetics may for example inhibit binding of ligand to EGFR, inhibit activation of EGFR, and/or reduce proliferation of tumor cells.Type: ApplicationFiled: June 14, 2005Publication date: June 16, 2011Inventors: Paul H. Kussie, Kathryn M. Ferguson